Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes
BOSTON--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June:
WATERTOWN, Mass.--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer. Dr. Dragone brings to Abata extensive experience in preclinical and early clinical development and autoimmune medicine. He will play a crucial role in advancing the development of Abata's programs in progressive multiple sclerosis (MS) and type 1 diabetes (T1D).
Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer
Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day
BOSTON--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer of Abata will participate in the following investor conferences in New York, NY.
BOSTON--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases, today announced the formation of the Abata Advisory Board, chaired by Diane Mathis, Ph.D., co-founder of Abata. The Abata Advisory Board brings together industry and scientific experts John Maraganore, Ph.D.; Charles Cooney, Ph.D.; and Gerald Nepom, M.D., Ph.D.; who will work with the Abata leadership team to create new possibilities for patients through Treg cell therapy.
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has strengthened its board of directors with the addition of Nagesh Mahanthappa Ph.D., M.B.A., and Valerie Odegard, Ph.D.